Industries We Serve
Cardiovascular Device Regulatory & Quality
Regulatory strategy and quality systems for blood-contacting and implantable cardiovascular devices — where the evidence bar is highest.
Overview
Cardiovascular devices sit at the top of the risk pyramid: most contact circulating blood, many are permanent implants, and a meaningful share carry life-supporting indications. That combination drives a regulatory and quality profile that is unforgiving of gaps — Class III PMA or De Novo for novel structural heart and electrophysiology technologies, clinical evidence under an IDE, and biocompatibility programs scoped for long-term blood and tissue contact. We help you build the strategy and the documentation that survive scrutiny, not just clear a checklist.
FDA Pathway & Classification
Cardiovascular devices span all three FDA classes, but the center of gravity is high. Many implants and life-supporting technologies — heart valves, ventricular assist devices, novel structural heart and electrophysiology systems — are Class III requiring a PMA, typically supported by a pivotal clinical study run under an IDE. Lower-risk or well-characterized devices may reach market via a De Novo (for novel low-to-moderate-risk types with no predicate) or a 510(k) when a legitimate predicate exists, such as certain guidewires, introducer sheaths, and diagnostic catheters. We pressure-test the pathway early, almost always through a Pre-Submission (Q-Sub), so FDA weighs in on study design and predicate logic before you spend. Under EU MDR, most cardiovascular implants are Class III, drawing the most rigorous clinical evaluation and Notified Body review.
Quality & Risk
The risk file is where cardiovascular programs are won or lost. ISO 14971 risk management has to address hazards that are specific and consequential — thrombosis, hemolysis, embolization, migration, fracture, lead dislodgement, and clinically relevant failure modes — with traceability from hazard to mitigation to verification. Biocompatibility under ISO 10993 must be scoped for the actual contact category: circulating-blood and permanent-implant endpoints, including hemocompatibility per ISO 10993-4, built on a chemical-characterization and toxicological-risk-assessment foundation (ISO 10993-18 and -17) rather than reflexive animal testing. Your ISO 13485 design controls have to carry that evidence cleanly into a design history file, and your QMS must hold up against the QMSR transition that aligns 21 CFR 820 to ISO 13485 in early 2026. CAPA, supplier controls, and software validation — for devices with firmware, algorithms, or programmers — round out the file.
In-Family Testing
Because Boulder is an FDA-registered, in-family operation, the testing your cardiovascular submission depends on does not get handed to strangers. Boulder BioLabs coordinates the microbiological and analytical work — bioburden, sterility, and endotoxin, plus the extractables and leachables and material characterization that anchor an ISO 10993 biological evaluation and toxicological risk assessment for blood-contacting devices. Boulder Sterilization runs validated EO and chlorine dioxide processing for terminally sterilized catheters, stents, and implants. Boulder Package Testing builds and validates the sterile barrier and shelf-life program under ISO 11607, including accelerated and real-time aging and distribution simulation — critical for implants that must stay sterile for years. Boulder iQ closes the loop on engineering and manufacturing when design or process refinement is needed.
We Live It, Not Just Advise It
We run an FDA-registered operation across sterilization, testing, and manufacturing — we live inside the same regulations we help you certify against, every day. So when we tell you what an FDA reviewer or a Notified Body will challenge on a blood-contacting implant, it is not theory; it is the bar we hold ourselves to. Operator-grade help, from people who actually operate.
Frequently Asked Questions
Is my cardiovascular device a 510(k), De Novo, or PMA?
It depends on risk and predicate. Many cardiovascular implants and life-supporting devices — heart valves, ventricular assist devices, novel structural heart and EP systems — are Class III and require a PMA backed by an IDE clinical study. Novel low-to-moderate-risk devices with no predicate often fit a De Novo, while devices with a legitimate predicate (certain guidewires, sheaths, diagnostic catheters) can go 510(k). We almost always confirm the route through a Pre-Submission so FDA agrees on classification and study design before you commit budget.
What biocompatibility testing does a blood-contacting cardiovascular device need?
Scope it to the real contact: circulating-blood, long-term, and permanent-implant endpoints under ISO 10993-1, including hemocompatibility per ISO 10993-4 (thrombosis, coagulation, hemolysis, complement, and platelet effects). Modern programs lead with chemical characterization and a toxicological risk assessment (ISO 10993-18 and -17) to justify endpoints and reduce unnecessary animal testing. Boulder BioLabs coordinates the extractables and leachables and analytical work that anchors that biological evaluation.
How do sterilization and shelf life factor into a cardiovascular submission?
For terminally sterilized catheters, stents, and implants, FDA and Notified Bodies expect a validated sterilization process (EO or chlorine dioxide) plus a validated sterile barrier and shelf-life program under ISO 11607 — accelerated and real-time aging and distribution simulation. Implants that must remain sterile for years live or die on that aging data. Boulder Sterilization and Boulder Package Testing run both in-family, so the validation evidence is generated under the same QMS that supports your filing.
Ready to Talk Through Your Cardiovascular Program?
Tell us where you are in the process. We respond within one business day.
Request a ConsultThe Boulder BioMed Family
One campus, one quality system. We manufacture, sterilize, and test medical devices in-house — so our regulatory and quality work is grounded in operations, not theory.